Thymosin Beta-4

Plain-English version: Thymosin beta-4 is a small natural protein fragment (a "peptide") that lives inside almost all of your cells. Its everyday job is to hold a reserve of actin — the protein your cells use to build their internal skeleton — so that skeleton can be rapidly rebuilt whenever a cell needs to move, divide, or crawl toward a wound. That cell-movement role is why researchers became interested in it for healing.

It was originally isolated from the thymus gland (an immune organ behind the breastbone) by Allan Goldstein's group as part of research into thymic hormones, which is where the "thymosin" name comes from. It was only later understood to be one of the most abundant peptides inside cells throughout the body, not just an immune-organ product.^[1] The molecule is 43 amino acids long. The World Health Organization assigned it the international nonproprietary name timbetasin.

Here is the relationship that trips people up: TB-500 is not the same thing as thymosin beta-4. TB-500 is a shorter, lab-made synthetic peptide built around the actin-binding region of thymosin beta-4 (the LKKTETQ sequence). It reproduces the key cell-migration activity but is not the full molecule. So thymosin beta-4 is the complete natural peptide with the more formal clinical-trial history, while TB-500 is the widely-sold fragment.

The credibility caveat, stated up front: "studied in humans" is true for thymosin beta-4, but only for topical formulations. The lead clinical candidate is RGN-259, a 0.1% thymosin beta-4 eye drop developed by RegeneRx Biopharmaceuticals for a corneal disease called neurotrophic keratopathy; it completed a Phase 3 trial and holds FDA Orphan Drug designation (granted 2013) for that condition.^[5] A topical skin gel (RGN-137) reached Phase 2 for chronic wounds. But no injectable or systemic form is FDA-approved for wound healing, cardiac repair, or musculoskeletal recovery, and no published human trial of subcutaneous thymosin beta-4 for muscle or joint injuries exists. Anything sold for injection is a research compound, not an approved drug. For the full legal breakdown, see Are Peptides Legal?

Takeaway first: Thymosin beta-4's core job is to manage actin, and from that one function a cascade of repair-related effects follows — cells can migrate to a wound, new blood vessels can form, and dying cells can be nudged to survive. Here is what the verified research actually shows, and where it stops.

1. Actin sequestration — the master function

Actin is a protein your cells use like scaffolding. It exists in two forms: free single units (G-actin) and assembled filaments (F-actin). To move or reshape itself, a cell must rapidly build and dismantle that scaffolding. Thymosin beta-4 is the major intracellular G-actin-sequestering peptide in mammalian cells — it grabs and holds a pool of free actin units, keeping them ready for instant deployment.^[1] This is the single best-established fact about the molecule, and every downstream "healing" claim traces back to it: controlled actin means controlled cell migration.

2. Cell migration and wound closure

Because it regulates that actin reserve, thymosin beta-4 promotes the migration of the cells that close wounds — keratinocytes (skin cells), endothelial cells (blood-vessel lining), and certain stem cells — toward the site of injury.^[2] Getting the right repair cells to the wound quickly is the foundation of healing, which is why so much of the research is in wound and corneal models. Evidence level: mechanistic, established across cell and animal work.

3. Angiogenesis, cell survival, and stem-cell signaling

Beyond moving cells, thymosin beta-4 has been described as promoting angiogenesis (new blood-vessel growth), supporting cell survival, and influencing stem-cell differentiation, while modulating inflammatory cytokines and tissue-remodeling enzymes (proteases).^[2] These are the properties that make it attractive across so many tissue types — but they are broad regulatory effects mapped mostly in cell culture and animals, not proven human outcomes.

4. The cardiac survival pathway (animal mechanism)

The mechanism that put thymosin beta-4 on the map came from a 2004 Nature paper. In mouse hearts, thymosin beta-4 formed a complex with two intracellular proteins (PINCH and integrin-linked kinase, "ILK"), which switched on the survival kinase Akt. After the coronary artery was tied off — a mouse model of heart attack — treated animals had better early heart-muscle-cell survival and improved cardiac function.^[4] This is an elegant, frequently-cited result, but it is worth repeating: it is a preclinical mouse study, not a human trial.

What we do NOT know

There is no established human pharmacokinetic profile for systemic thymosin beta-4 (how an injected dose is absorbed, distributed, and cleared in people), no human dose-response data for injection, and no confirmed human efficacy for cardiac or musculoskeletal repair. The mechanisms above are real, published findings — but the strongest of them live in mice and cell cultures, and mechanism in animals does not guarantee benefit in humans.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied (this is the part most articles skip), the observed effect, and the limitation. Notice which benefits are backed by human trials and which are still animal-only — that distinction is the whole point.

Corneal (eye) wound healing — the strongest human evidence

Claim: may heal stubborn corneal wounds. Mechanism: actin-driven migration of corneal cells across the wound, plus anti-inflammatory activity. Population: HUMAN — an 18-patient randomized, placebo-controlled, double-masked Phase 3 trial of 0.1% RGN-259 (thymosin beta-4) eye drops in neurotrophic keratopathy, a disease where the cornea will not heal on its own. Effect: complete corneal healing occurred in 6 of 10 treated patients versus 1 of 8 on placebo at day 29 (60% vs 12.5%, p=0.0656), and by day 43 — two weeks after treatment ended — 5 of 10 treated patients maintained healing versus 0 of 8 on placebo (p=0.0359), with improvements in ocular discomfort and dryness.^[5] Limitation: small sample, a single eye indication, and the day-29 primary comparison narrowly missed statistical significance. This is genuine human evidence, but for eye drops — not for injection.

Skin (dermal) wound healing — human Phase 2 plus animal support

Claim: may speed the closure of chronic skin wounds. Mechanism: keratinocyte and endothelial migration, angiogenesis, and reduced inflammation. Population: HUMAN Phase 2 trials of topical thymosin beta-4 in pressure ulcers, venous stasis ulcers, and epidermolysis bullosa wounds, backed by preclinical diabetic, aged, and burn animal models. Effect: topical thymosin beta-4 accelerated dermal repair across these settings, with angiogenic and anti-inflammatory activity described as the driver.^[7] Limitation: Phase 2 is early-stage; these were topical gel formulations for open wounds, and the results have not been extended to systemic or musculoskeletal use.

Cardiac repair — promising but animal-only

Claim: may protect and repair heart muscle after a heart attack. Mechanism: the PINCH/ILK/Akt survival pathway, activation of epicardial progenitor cells, and new coronary vessel growth. Population: mice with surgically induced heart attacks (coronary artery ligation). Effect: thymosin beta-4 upregulated ILK and Akt, improved early heart-muscle-cell survival, and improved cardiac function.^[4] Limitation: this is the benefit most often overstated online. It is a mouse result. There is no completed human trial showing thymosin beta-4 repairs a human heart, and you should not read the animal data as a human outcome.

Musculoskeletal recovery — the popular use, the thinnest evidence

Claim: may speed recovery from muscle, tendon, and ligament injuries. Mechanism: the same actin/migration and angiogenic pathways that drive wound healing. Population: this is where the honesty gap is largest — the injury-recovery reputation rides mostly on the actin/migration mechanism and on data for its fragment TB-500, not on published human trials of full-length thymosin beta-4 for muscle or joint injury. Effect: plausible on mechanism, but no published subcutaneous/systemic human trial for musculoskeletal recovery was found. Limitation: treat athletic-recovery claims as extrapolation, not proven benefit. This is the single most-searched use case and the least supported by direct human data.

Anti-inflammatory and regenerative signaling

Claim: may calm inflammation and create a pro-repair environment. Mechanism: cytokine and protease modulation alongside its migration and survival effects. Population: cell and animal models across the reviews. Effect: reduced inflammatory signaling that complements tissue repair.^[2][3] Limitation: mechanistic and preclinical; not a demonstrated treatment for any inflammatory disease in humans.

The honest bottom line on "benefits"

• Human evidence exists but is topical. Eye drops (Phase 3) and skin gel (Phase 2) are the real human data points; injection is not.^[5][7]
• The cardiac story is preclinical. Improved heart function and smaller infarcts are mouse findings.^[4]
• Musculoskeletal use is extrapolation. No published human injection trial for muscle/joint recovery was found.
• Anecdotes are not data. Enthusiastic user reports cannot substitute for controlled trials.

Read this first: the only well-documented human doses of thymosin beta-4 are topical. The published clinical formulations are the 0.1% RGN-259 ophthalmic solution (eye drops) for corneal indications and a topical gel (RGN-137) for skin ulcers.^[5][6] The subcutaneous milligram-range figures circulating in "research" communities are not drawn from these trials and should not be presented as clinically validated. We describe them below for completeness and harm reduction, not as medical guidance.

Documented clinical formulations (topical, from published work)

Formulation	Concentration / route	Indication studied	Evidence
RGN-259 eye drops	0.1% ophthalmic solution, topical to the eye	Neurotrophic keratopathy	HUMAN Phase 3[5]
RGN-137 gel	Topical to the wound	Pressure/venous ulcers, epidermolysis bullosa	HUMAN Phase 2[6][7]

Commonly cited injection protocols (extrapolated, NOT validated)

Research communities typically borrow a loading-and-maintenance structure from TB-500. We stress again: these figures are not from any published thymosin beta-4 human trial.

Phase	Commonly cited dose	Frequency	Duration
Loading (extrapolated)	Often quoted around 2-2.5 mg/week, split across doses	2× weekly	4-6 weeks
Maintenance (extrapolated)	Lower quoted weekly total	Once weekly to biweekly	Ongoing per protocol

Thymosin beta-4 is described as acting systemically, so protocols do not require injecting near an injury. None of this is trial-derived; it is convention layered on top of fragment (TB-500) practice.

Reconstitution math, with a worked example

Research-grade thymosin beta-4 ships as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: take a 10 mg vial and add 2 mL of bacteriostatic water. That gives 10 ÷ 2 = 5 mg/mL, i.e. 5,000 mcg per mL. To draw a hypothetical 1,250 mcg (1.25 mg) dose: 1,250 ÷ 5,000 = 0.25 mL, which is 25 units on a standard 100-unit insulin syringe. A 2.5 mg dose would be 0.50 mL, or 50 units.

Vial	BAC water	Concentration	1.25 mg dose	2.5 mg dose
10 mg	2 mL	5.0 mg/mL	0.25 mL (25 units)	0.50 mL (50 units)
10 mg	1 mL	10.0 mg/mL	0.125 mL (12.5 units)	0.25 mL (25 units)
5 mg	1 mL	5.0 mg/mL	0.25 mL (25 units)	0.50 mL (50 units)

Preparation steps: wipe the vial stopper with alcohol; draw the water; inject it slowly down the inside wall rather than blasting the powder; swirl gently (do not shake) until fully dissolved; label the vial with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a full walkthrough.

Cycle length, timing, and storage

• Timing: injectable protocols report no strict meal or time-of-day requirement.
• Cycle: extrapolated protocols commonly run a 4-6 week loading block followed by reduced maintenance; these durations are convention, not trial-derived.
• Storage: keep lyophilized vials frozen (-20°C) for long-term storage or refrigerated (2-8°C) for shorter periods; once reconstituted, refrigerate at 2-8°C and use within about 28 days. See the peptide storage guide.

None of the above should be read as a recommendation to self-administer an unapproved compound. It is a description of how research doses are structured, with an explicit warning that the injection figures have no human-trial basis.

Straight talk: thymosin beta-4 has more human safety data than most research peptides — but that data is from topical use. In the RGN-259 eye-drop Phase 3 trial, 16 adverse events occurred across 7 subjects, only one was judged treatment-related, and none caused anyone to withdraw — a favorable ocular safety profile.^[5] A European randomized venous-ulcer study likewise evaluated topical thymosin beta-4 for safety and tolerability alongside compression therapy over an 84-day treatment period.^[6] What this does not establish is the safety of injected, systemic thymosin beta-4, for which controlled human safety data do not exist.

Reported side effects (topical trials and user experience)

Effect	Frequency	Severity	Notes
Injection-site redness/irritation	Common (injection use)	Mild	Transient; typical of subcutaneous injection
Eye stinging/tearing	Occasional (eye drops)	Mild	Reported with the ophthalmic formulation
Fatigue	Occasional	Mild	Transient tiredness reported by some users
Headache	Occasional	Mild	Transient

Theoretical risks and who should avoid it

• Active cancer (theoretical caution): thymosin beta-4's pro-migratory and pro-angiogenic actions are exactly the properties a tumor would exploit to grow and spread, which creates a theoretical concern in active malignancy. Importantly, the reviews describe it as pro-regenerative, and causality regarding tumor promotion in humans is not established — so this is a theoretical caution, not a demonstrated risk. It is still generally treated as off-limits for anyone with active or recent cancer until specifically studied.
• Pregnancy and breastfeeding: not studied in these populations — avoid.
• Competitive athletes: thymosin beta-4 is prohibited in sport by the World Anti-Doping Agency (WADA), so athletes subject to testing should treat it as bannable.
• Long-term systemic use: the long-term effects of sustained injected administration are not characterized.

The limitations you must keep in mind

• The favorable safety data are for topical eye and skin formulations, not injection.
• No controlled human safety trial of systemic/injected thymosin beta-4 exists, so injected pharmacokinetics, drug interactions, and long-term safety are unknown.
• Product-quality problems — impurities in unregulated research vials — are a real and separate hazard that can cause effects wrongly blamed on the peptide.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: injectable thymosin beta-4 is an unregulated research compound, so purity and identity vary enormously between suppliers. For an unproven injectable, contamination is arguably a bigger practical risk than the peptide itself. Knowing how to read a Certificate of Analysis (COA) is the single most useful skill here.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight for the 43-amino-acid peptide.
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed liquid "ready to use" peptide (shorter shelf life, contamination risk)
• Prices far below the market
• Explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor
• Product sold as "thymosin beta-4" at a fragment price — confirm you are not actually buying TB-500 relabeled

Legal and regulatory status (2026)

• Not FDA-approved for any indication. Full-length thymosin beta-4 is investigational.
• Orphan Drug designation (eye drops only): the RGN-259 (0.1% thymosin beta-4) ophthalmic solution holds FDA Orphan Drug designation (granted 2013) for neurotrophic keratopathy, with confirmatory Phase 3 trials reported as ongoing. This applies to the eye drop, not to any injectable form.^[5]
• No approved systemic form: no injectable or systemic thymosin beta-4 is approved for wound healing, cardiac repair, musculoskeletal recovery, or any other use.
• Prohibited in sport: WADA bans thymosin beta-4 in competitive sport.
• WHO name: the international nonproprietary name is timbetasin.

Anything sold for research or injection is not an approved drug. For the complete legal picture, read Are Peptides Legal?

Thymosin beta-4 is usually weighed against two neighbors. None of these comparisons are backed by head-to-head human trials — they contrast the molecules, their mechanisms, and the research base.

Thymosin Beta-4 vs. TB-500

Factor	Thymosin Beta-4	TB-500
What it is	Full-length natural 43-amino-acid peptide	Synthetic fragment of the active region (LKKTETQ)
Research pedigree	Human topical trials (Phase 2/3) plus animal work	Mostly preclinical; popular in research settings
Availability / cost	Less common, generally pricier	Widely available, more affordable
Core mechanism	Both act through actin regulation and cell migration

In short: thymosin beta-4 is the full molecule with the stronger formal-trial history (topical), while TB-500 is the cheaper, more accessible fragment that reproduces the key active region.

Thymosin Beta-4 vs. BPC-157

BPC-157 works through different proposed pathways — angiogenesis via VEGFR2 and nitric-oxide-system balancing — and is oriented toward tendon, ligament, and gut repair, with an unusual tolerance for stomach acid that allows oral use. Thymosin beta-4 leads with actin-driven cell migration and has the topical human-trial data. They target repair from different angles, which is why healing-focused discussions often mention them together rather than as direct rivals.